IMUNON, a cutting-edge biotechnology firm dedicated to developing innovative treatments utilizing the body’s natural defense mechanisms, has successfully raised $10 million in its latest funding round. As a clinical-stage company at the forefront of cancer and infectious disease therapies, IMUNON is excited to channel these funds into the advancement of its transformative portfolio. Central to its endeavors is the TheraPlas® platform, an innovative technology that facilitates the creation of immunotherapies alongside anti-cancer nucleic acid-based therapies. The flagship program, GEN-1, is currently in Phase II clinical trials and targets advanced ovarian cancer by harnessing the body's own immune response to produce vital cancer-fighting molecules such as interleukin-12 (IL-12) and interferon gamma (IFN-γ) specifically at the tumor site. Additionally, IMUNON is venturing into pre-clinical studies for a nucleic acid vaccine against the SARS-CoV-2 virus, underscoring the versatility of its PLACCINE platform in addressing both cancer and infectious diseases. The recent funding will enable IMUNON to enhance its technological capabilities further and continue pioneering its novel synthetic delivery systems, which do not rely on viral vectors. With a strong commitment to revolutionizing treatment for patients faced with challenging medical conditions, IMUNON is poised to make significant advancements in the biotechnology landscape, making strides toward improved healthcare outcomes.
IMUNON Secures $10 Million in Funding for Revolutionary Biotechnology Solutions
Recently funded · $10.0MBiotechnology
Get the full IMUNON company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
